Table 3.
Average ON and OFF values and their changes in MDS-UPDRS and PDCS motor scores by disease type during levodopa challenge.
| Disease type | ||||
|---|---|---|---|---|
| Tremor-dominant PD | Rigid-akinetic PD | Mixed PD | Non-PD (other parkinsonian syndromes) | |
| MDS-UPDRS OFF (points) | 45.3 ± 15.3 | 43.3 ± 16.5 | 48.3 ± 15.4 | 44.3 ± 13.1 |
| MDS-UPDRS ON (points) | 31.3 ± 13.5 | 29.6 ± 17.00 | 35.3 ± 13.9 | 40.5 ± 13.5 |
| MDS-UPDRS change (points) | −14.0 ± 10.6 | −13.7 ± 10.3 | −13.1 ± 10.5 | −3.8 ± 2.4 |
| MDS-UPDRS change (%) | −29.7 ± 20.6 | −33.5 ± 21.6 | −26.9 ± 16.7 | −9.9 ± 8.3 |
| PDCS OFF (points) | 12.0 ± 5.8 | 14.0 ± 6.8 | 14.2 ± 5.7 | 14.8 ± 6.0 |
| PDCS ON (points) | 8.0 ± 5.4 | 8.8 ± 7.0 | 11.3 ± 5.8 | 14.1 ± 6.0 |
| PDCS change (points) | −4.0 ± 3.8 | −5.2 ± 4.7 | −2.9 ± 3.2 | −0.7 ± 1.0 |
| PDCS change (%) | −33.0 ± 28.0 | −42.0 ± 34.7 | −21.6 ± 24.5 | −5.6 ± 8.2 |
| Correlation (Spearman's rho) between changes in MDS-UPDRS (%) and PDCS (%) | 0.806 (p < 0.001) | 0.776 (p < 0.001) | 0.685 (p < 0.001) | 0.465 (p < 0.001) |
Data are mean ± standard deviation. Assessments in OFF state were performed at least 12 hours after the discontinuation of any antiparkinsonian medication. Patients were reassessed 60 minutes after a single dose of 200–400 mg immediate-release formulation of levodopa/benserazide or in the best ON state. MDS-UPDRS = Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale; PD = Parkinson's disease; PDCS = Parkinson's Disease Composite Scale.